Back to Search
Start Over
Use of Ruxolitinib for the Simultaneous Treatment of Severe Refractory Ulcerative Colitis and Polycythemia Vera.
- Source :
-
ACG case reports journal [ACG Case Rep J] 2022 Jan 06; Vol. 9 (1), pp. e00741. Date of Electronic Publication: 2022 Jan 06 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- Tofacitinib is the only medicine in the class of Janus kinase (JAK) inhibitors that has been approved for use in moderate-to-severely active ulcerative colitis (UC). The potential of other JAK inhibitors to treat UC has not been fully explored. We present a case describing the successful use of the selective JAK inhibitor, ruxolitinib, to treat a patient with concomitant UC and polycythemia vera.<br /> (© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.)
Details
- Language :
- English
- ISSN :
- 2326-3253
- Volume :
- 9
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- ACG case reports journal
- Publication Type :
- Report
- Accession number :
- 35018293
- Full Text :
- https://doi.org/10.14309/crj.0000000000000741